Titre : Sulfonamides

Sulfonamides : Questions médicales fréquentes

Termes MeSH sélectionnés :

Blood Component Transfusion

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une infection nécessitant des sulfonamides ?

Un diagnostic repose sur des symptômes cliniques et des cultures bactériennes.
Infections bactériennes Diagnostic médical
#2

Quels tests sont utilisés pour évaluer l'efficacité des sulfonamides ?

Des tests de sensibilité aux antibiotiques sont réalisés sur des échantillons microbiologiques.
Sensibilité aux antibiotiques Tests de laboratoire
#3

Les sulfonamides sont-ils efficaces contre toutes les bactéries ?

Non, leur efficacité varie selon le type de bactérie et leur résistance.
Résistance bactérienne Antibiotiques
#4

Quels signes cliniques indiquent une infection bactérienne ?

Fièvre, douleur, rougeur et gonflement peuvent indiquer une infection.
Symptômes Infections bactériennes
#5

Comment confirmer une infection urinaire ?

Un examen d'urine et une culture permettent de confirmer une infection urinaire.
Infection urinaire Culture bactérienne

Symptômes 5

#1

Quels sont les symptômes d'une infection traitée par sulfonamides ?

Fièvre, douleur, fatigue et symptômes locaux selon l'infection.
Symptômes Infections bactériennes
#2

Les sulfonamides provoquent-ils des effets secondaires ?

Oui, des effets comme éruptions cutanées, nausées ou réactions allergiques peuvent survenir.
Effets secondaires Réactions allergiques
#3

Comment reconnaître une réaction allergique aux sulfonamides ?

Éruptions cutanées, démangeaisons, ou gonflement peuvent indiquer une allergie.
Allergies médicamenteuses Eruptions cutanées
#4

Quels symptômes indiquent une surinfection ?

Augmentation de la douleur, fièvre persistante et écoulement purulent peuvent indiquer une surinfection.
Surinfection Symptômes
#5

Les sulfonamides peuvent-ils causer des troubles gastro-intestinaux ?

Oui, des nausées, vomissements ou diarrhées peuvent survenir avec leur utilisation.
Troubles gastro-intestinaux Effets secondaires

Prévention 5

#1

Comment prévenir les infections nécessitant des sulfonamides ?

Maintenir une bonne hygiène, se faire vacciner et éviter les contacts avec des malades.
Prévention des infections Hygiène
#2

Les sulfonamides peuvent-ils être utilisés en prophylaxie ?

Oui, ils peuvent être prescrits en prophylaxie pour prévenir certaines infections.
Prophylaxie Antibiotiques
#3

Quelles mesures d'hygiène sont recommandées ?

Se laver les mains régulièrement et éviter le partage d'objets personnels.
Hygiène Prévention des infections
#4

Les vaccinations aident-elles à prévenir les infections ?

Oui, certaines vaccinations peuvent réduire le risque d'infections bactériennes.
Vaccination Prévention des infections
#5

Comment éviter la résistance aux antibiotiques ?

Utiliser les antibiotiques uniquement lorsque prescrit et suivre les recommandations médicales.
Résistance aux antibiotiques Utilisation des médicaments

Traitements 5

#1

Comment les sulfonamides sont-ils administrés ?

Ils sont généralement administrés par voie orale ou intraveineuse selon l'infection.
Administration médicamenteuse Antibiotiques
#2

Quelle est la posologie habituelle des sulfonamides ?

La posologie varie selon l'infection, mais doit être prescrite par un médecin.
Posologie Antibiotiques
#3

Les sulfonamides peuvent-ils être combinés avec d'autres antibiotiques ?

Oui, ils peuvent être utilisés en association pour élargir le spectre d'action.
Thérapie combinée Antibiotiques
#4

Quel suivi est nécessaire lors d'un traitement par sulfonamides ?

Un suivi régulier pour surveiller les effets secondaires et l'efficacité est recommandé.
Suivi médical Effets secondaires
#5

Les sulfonamides sont-ils efficaces contre les infections virales ?

Non, les sulfonamides ne sont pas efficaces contre les infections virales.
Infections virales Antibiotiques

Complications 5

#1

Quelles complications peuvent survenir avec les sulfonamides ?

Des réactions allergiques graves, des troubles sanguins ou des lésions hépatiques peuvent survenir.
Complications Effets secondaires
#2

Comment gérer une réaction allergique sévère aux sulfonamides ?

Cesser immédiatement le traitement et consulter un médecin pour un traitement approprié.
Réactions allergiques Urgences médicales
#3

Les sulfonamides peuvent-ils causer des troubles rénaux ?

Oui, des troubles rénaux peuvent survenir, nécessitant une surveillance de la fonction rénale.
Troubles rénaux Effets secondaires
#4

Quels signes indiquent une complication grave ?

Fièvre élevée, éruption cutanée étendue ou difficulté respiratoire peuvent indiquer une complication.
Complications Symptômes
#5

Les sulfonamides peuvent-ils interagir avec d'autres médicaments ?

Oui, ils peuvent interagir avec d'autres médicaments, augmentant le risque d'effets secondaires.
Interactions médicamenteuses Effets secondaires

Facteurs de risque 5

#1

Qui est à risque de développer des effets secondaires aux sulfonamides ?

Les personnes ayant des antécédents d'allergies médicamenteuses sont à risque accru.
Facteurs de risque Allergies médicamenteuses
#2

Les personnes âgées sont-elles plus à risque avec les sulfonamides ?

Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications.
Personnes âgées Effets secondaires
#3

Les femmes enceintes peuvent-elles prendre des sulfonamides ?

L'utilisation doit être évitée, car elle peut affecter le fœtus. Consultez un médecin.
Grossesse Antibiotiques
#4

Les patients atteints de maladies hépatiques sont-ils à risque ?

Oui, ils peuvent avoir un risque accru d'effets indésirables et nécessitent une surveillance.
Maladies hépatiques Effets secondaires
#5

Les antécédents d'infections récurrentes augmentent-ils le risque ?

Oui, les antécédents d'infections récurrentes peuvent nécessiter un traitement plus agressif.
Infections récurrentes Facteurs de risque
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Sulfonamides : Questions médicales les plus fréquentes", "headline": "Sulfonamides : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Sulfonamides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-25", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Sulfonamides" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Sulfones", "url": "https://questionsmedicales.fr/mesh/D013450", "about": { "@type": "MedicalCondition", "name": "Sulfones", "code": { "@type": "MedicalCode", "code": "D013450", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bumétanide", "alternateName": "Bumetanide", "url": "https://questionsmedicales.fr/mesh/D002034", "about": { "@type": "MedicalCondition", "name": "Bumétanide", "code": { "@type": "MedicalCode", "code": "D002034", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.150" } } }, { "@type": "MedicalWebPage", "name": "Diclofénamide", "alternateName": "Dichlorphenamide", "url": "https://questionsmedicales.fr/mesh/D004005", "about": { "@type": "MedicalCondition", "name": "Diclofénamide", "code": { "@type": "MedicalCode", "code": "D004005", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.410" } } }, { "@type": "MedicalWebPage", "name": "Mafénide", "alternateName": "Mafenide", "url": "https://questionsmedicales.fr/mesh/D008272", "about": { "@type": "MedicalCondition", "name": "Mafénide", "code": { "@type": "MedicalCode", "code": "D008272", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.570" } } }, { "@type": "MedicalWebPage", "name": "Méfruside", "alternateName": "Mefruside", "url": "https://questionsmedicales.fr/mesh/D008529", "about": { "@type": "MedicalCondition", "name": "Méfruside", "code": { "@type": "MedicalCode", "code": "D008529", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.575" } } }, { "@type": "MedicalWebPage", "name": "Probénécide", "alternateName": "Probenecid", "url": "https://questionsmedicales.fr/mesh/D011339", "about": { "@type": "MedicalCondition", "name": "Probénécide", "code": { "@type": "MedicalCode", "code": "D011339", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.625" } } }, { "@type": "MedicalWebPage", "name": "Sulfamides", "alternateName": "Sulfanilamides", "url": "https://questionsmedicales.fr/mesh/D013424", "about": { "@type": "MedicalCondition", "name": "Sulfamides", "code": { "@type": "MedicalCode", "code": "D013424", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Furosémide", "alternateName": "Furosemide", "url": "https://questionsmedicales.fr/mesh/D005665", "about": { "@type": "MedicalCondition", "name": "Furosémide", "code": { "@type": "MedicalCode", "code": "D005665", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.300" } } }, { "@type": "MedicalWebPage", "name": "Sulfacétamide", "alternateName": "Sulfacetamide", "url": "https://questionsmedicales.fr/mesh/D013409", "about": { "@type": "MedicalCondition", "name": "Sulfacétamide", "code": { "@type": "MedicalCode", "code": "D013409", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.650" } } }, { "@type": "MedicalWebPage", "name": "Sulfachlorpyridazine", "alternateName": "Sulfachlorpyridazine", "url": "https://questionsmedicales.fr/mesh/D013410", "about": { "@type": "MedicalCondition", "name": "Sulfachlorpyridazine", "code": { "@type": "MedicalCode", "code": "D013410", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.700" } } }, { "@type": "MedicalWebPage", "name": "Sulfadiazine", "alternateName": "Sulfadiazine", "url": "https://questionsmedicales.fr/mesh/D013411", "about": { "@type": "MedicalCondition", "name": "Sulfadiazine", "code": { "@type": "MedicalCode", "code": "D013411", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.755" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Sulfadiazine d'argent", "alternateName": "Silver Sulfadiazine", "url": "https://questionsmedicales.fr/mesh/D012837", "about": { "@type": "MedicalCondition", "name": "Sulfadiazine d'argent", "code": { "@type": "MedicalCode", "code": "D012837", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.755.800" } } } ] }, { "@type": "MedicalWebPage", "name": "Sulfadiazine d'argent", "alternateName": "Silver Sulfadiazine", "url": "https://questionsmedicales.fr/mesh/D012837", "about": { "@type": "MedicalCondition", "name": "Sulfadiazine d'argent", "code": { "@type": "MedicalCode", "code": "D012837", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.755.800" } } }, { "@type": "MedicalWebPage", "name": "Sulfadiméthoxine", "alternateName": "Sulfadimethoxine", "url": "https://questionsmedicales.fr/mesh/D013412", "about": { "@type": "MedicalCondition", "name": "Sulfadiméthoxine", "code": { "@type": "MedicalCode", "code": "D013412", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.760" } } }, { "@type": "MedicalWebPage", "name": "Sulfadoxine", "alternateName": "Sulfadoxine", "url": "https://questionsmedicales.fr/mesh/D013413", "about": { "@type": "MedicalCondition", "name": "Sulfadoxine", "code": { "@type": "MedicalCode", "code": "D013413", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.765" } } }, { "@type": "MedicalWebPage", "name": "Sulfaguanidine", "alternateName": "Sulfaguanidine", "url": "https://questionsmedicales.fr/mesh/D013414", "about": { "@type": "MedicalCondition", "name": "Sulfaguanidine", "code": { "@type": "MedicalCode", "code": "D013414", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.810" } } }, { "@type": "MedicalWebPage", "name": "Sulfalène", "alternateName": "Sulfalene", "url": "https://questionsmedicales.fr/mesh/D013415", "about": { "@type": "MedicalCondition", "name": "Sulfalène", "code": { "@type": "MedicalCode", "code": "D013415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.850" } } }, { "@type": "MedicalWebPage", "name": "Sulfamérazine", "alternateName": "Sulfamerazine", "url": "https://questionsmedicales.fr/mesh/D013416", "about": { "@type": "MedicalCondition", "name": "Sulfamérazine", "code": { "@type": "MedicalCode", "code": "D013416", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.853" } } }, { "@type": "MedicalWebPage", "name": "Sulfamétoxydiazine", "alternateName": "Sulfameter", "url": "https://questionsmedicales.fr/mesh/D013417", "about": { "@type": "MedicalCondition", "name": "Sulfamétoxydiazine", "code": { "@type": "MedicalCode", "code": "D013417", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.857" } } }, { "@type": "MedicalWebPage", "name": "Sulfadimidine", "alternateName": "Sulfamethazine", "url": "https://questionsmedicales.fr/mesh/D013418", "about": { "@type": "MedicalCondition", "name": "Sulfadimidine", "code": { "@type": "MedicalCode", "code": "D013418", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.862" } } }, { "@type": "MedicalWebPage", "name": "Sulfaméthoxazole", "alternateName": "Sulfamethoxazole", "url": "https://questionsmedicales.fr/mesh/D013420", "about": { "@type": "MedicalCondition", "name": "Sulfaméthoxazole", "code": { "@type": "MedicalCode", "code": "D013420", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.867" } } }, { "@type": "MedicalWebPage", "name": "Sulfaméthoxypyridazine", "alternateName": "Sulfamethoxypyridazine", "url": "https://questionsmedicales.fr/mesh/D013421", "about": { "@type": "MedicalCondition", "name": "Sulfaméthoxypyridazine", "code": { "@type": "MedicalCode", "code": "D013421", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.872" } } }, { "@type": "MedicalWebPage", "name": "Sulfamonométhoxine", "alternateName": "Sulfamonomethoxine", "url": "https://questionsmedicales.fr/mesh/D013422", "about": { "@type": "MedicalCondition", "name": "Sulfamonométhoxine", "code": { "@type": "MedicalCode", "code": "D013422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.877" } } }, { "@type": "MedicalWebPage", "name": "Sulfamoxole", "alternateName": "Sulfamoxole", "url": "https://questionsmedicales.fr/mesh/D013423", "about": { "@type": "MedicalCondition", "name": "Sulfamoxole", "code": { "@type": "MedicalCode", "code": "D013423", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.882" } } }, { "@type": "MedicalWebPage", "name": "Sulfanilamide", "alternateName": "Sulfanilamide", "url": "https://questionsmedicales.fr/mesh/D000077145", "about": { "@type": "MedicalCondition", "name": "Sulfanilamide", "code": { "@type": "MedicalCode", "code": "D000077145", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.885" } } }, { "@type": "MedicalWebPage", "name": "Sulfapyridine", "alternateName": "Sulfapyridine", "url": "https://questionsmedicales.fr/mesh/D013427", "about": { "@type": "MedicalCondition", "name": "Sulfapyridine", "code": { "@type": "MedicalCode", "code": "D013427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.900" } } }, { "@type": "MedicalWebPage", "name": "Sulfaquinoxaline", "alternateName": "Sulfaquinoxaline", "url": "https://questionsmedicales.fr/mesh/D013428", "about": { "@type": "MedicalCondition", "name": "Sulfaquinoxaline", "code": { "@type": "MedicalCode", "code": "D013428", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.925" } } }, { "@type": "MedicalWebPage", "name": "Sulfaméthizol", "alternateName": "Sulfamethizole", "url": "https://questionsmedicales.fr/mesh/D013419", "about": { "@type": "MedicalCondition", "name": "Sulfaméthizol", "code": { "@type": "MedicalCode", "code": "D013419", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.935.813" } } }, { "@type": "MedicalWebPage", "name": "Sulfisomidine", "alternateName": "Sulfisomidine", "url": "https://questionsmedicales.fr/mesh/D013443", "about": { "@type": "MedicalCondition", "name": "Sulfisomidine", "code": { "@type": "MedicalCode", "code": "D013443", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.940" } } }, { "@type": "MedicalWebPage", "name": "Sulfafurazol", "alternateName": "Sulfisoxazole", "url": "https://questionsmedicales.fr/mesh/D013444", "about": { "@type": "MedicalCondition", "name": "Sulfafurazol", "code": { "@type": "MedicalCode", "code": "D013444", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.725.945" } } } ] }, { "@type": "MedicalWebPage", "name": "Sulfasalazine", "alternateName": "Sulfasalazine", "url": "https://questionsmedicales.fr/mesh/D012460", "about": { "@type": "MedicalCondition", "name": "Sulfasalazine", "code": { "@type": "MedicalCode", "code": "D012460", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.730" } } }, { "@type": "MedicalWebPage", "name": "Tamsulosine", "alternateName": "Tamsulosin", "url": "https://questionsmedicales.fr/mesh/D000077409", "about": { "@type": "MedicalCondition", "name": "Tamsulosine", "code": { "@type": "MedicalCode", "code": "D000077409", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.863" } } }, { "@type": "MedicalWebPage", "name": "Xipamide", "alternateName": "Xipamide", "url": "https://questionsmedicales.fr/mesh/D014988", "about": { "@type": "MedicalCondition", "name": "Xipamide", "code": { "@type": "MedicalCode", "code": "D014988", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.886.590.700.975" } } } ], "about": { "@type": "MedicalCondition", "name": "Sulfonamides", "alternateName": "Sulfonamides", "code": { "@type": "MedicalCode", "code": "D013449", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Reihane Ghomashi", "url": "https://questionsmedicales.fr/author/Reihane%20Ghomashi", "affiliation": { "@type": "Organization", "name": "Department of Medicinal Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran." } }, { "@type": "Person", "name": "Shakila Ghomashi", "url": "https://questionsmedicales.fr/author/Shakila%20Ghomashi", "affiliation": { "@type": "Organization", "name": "Department of Medicinal Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran." } }, { "@type": "Person", "name": "Hamidreza Aghaei", "url": "https://questionsmedicales.fr/author/Hamidreza%20Aghaei", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran." } }, { "@type": "Person", "name": "Ahmad Reza Massah", "url": "https://questionsmedicales.fr/author/Ahmad%20Reza%20Massah", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran." } }, { "@type": "Person", "name": "Satoru Suzuki", "url": "https://questionsmedicales.fr/author/Satoru%20Suzuki", "affiliation": { "@type": "Organization", "name": "Leading Academia in Marine and Environment Pollution Research (LaMer), Center for Marine Environmental Studies (CMES), Ehime University, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "How do I/we forecast tomorrows' transfusion: Blood components.", "datePublished": "2022-07-30", "url": "https://questionsmedicales.fr/article/35914702", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.tracli.2022.07.006" } }, { "@type": "ScholarlyArticle", "name": "Balanced blood component resuscitation in trauma: Does it matter equally at different transfusion volumes?", "datePublished": "2022-12-15", "url": "https://questionsmedicales.fr/article/36528406", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.surg.2022.11.010" } }, { "@type": "ScholarlyArticle", "name": "Influence of the leukoreduction moment of blood components on the clinical outcomes of transfused patients in the emergency department.", "datePublished": "2024-08-26", "url": "https://questionsmedicales.fr/article/39194129", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/0034-7167-2023-0293" } }, { "@type": "ScholarlyArticle", "name": "Hypocalcemia in Trauma is Determined by the Number of Units Transfused, Not Whole Blood Versus Component Therapy.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37148855", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jss.2023.03.043" } }, { "@type": "ScholarlyArticle", "name": "Parents' understanding and experiences of blood component transfusion in the neonatal intensive care unit: A qualitative study.", "datePublished": "2023-08-24", "url": "https://questionsmedicales.fr/article/37615240", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/apa.16952" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Composés du soufre", "item": "https://questionsmedicales.fr/mesh/D013457" }, { "@type": "ListItem", "position": 4, "name": "Sulfones", "item": "https://questionsmedicales.fr/mesh/D013450" }, { "@type": "ListItem", "position": 5, "name": "Sulfonamides", "item": "https://questionsmedicales.fr/mesh/D013449" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Sulfonamides - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Sulfonamides", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Sulfonamides", "description": "Comment diagnostiquer une infection nécessitant des sulfonamides ?\nQuels tests sont utilisés pour évaluer l'efficacité des sulfonamides ?\nLes sulfonamides sont-ils efficaces contre toutes les bactéries ?\nQuels signes cliniques indiquent une infection bactérienne ?\nComment confirmer une infection urinaire ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Sulfonamides", "description": "Quels sont les symptômes d'une infection traitée par sulfonamides ?\nLes sulfonamides provoquent-ils des effets secondaires ?\nComment reconnaître une réaction allergique aux sulfonamides ?\nQuels symptômes indiquent une surinfection ?\nLes sulfonamides peuvent-ils causer des troubles gastro-intestinaux ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Sulfonamides", "description": "Comment prévenir les infections nécessitant des sulfonamides ?\nLes sulfonamides peuvent-ils être utilisés en prophylaxie ?\nQuelles mesures d'hygiène sont recommandées ?\nLes vaccinations aident-elles à prévenir les infections ?\nComment éviter la résistance aux antibiotiques ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Sulfonamides", "description": "Comment les sulfonamides sont-ils administrés ?\nQuelle est la posologie habituelle des sulfonamides ?\nLes sulfonamides peuvent-ils être combinés avec d'autres antibiotiques ?\nQuel suivi est nécessaire lors d'un traitement par sulfonamides ?\nLes sulfonamides sont-ils efficaces contre les infections virales ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Sulfonamides", "description": "Quelles complications peuvent survenir avec les sulfonamides ?\nComment gérer une réaction allergique sévère aux sulfonamides ?\nLes sulfonamides peuvent-ils causer des troubles rénaux ?\nQuels signes indiquent une complication grave ?\nLes sulfonamides peuvent-ils interagir avec d'autres médicaments ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Sulfonamides", "description": "Qui est à risque de développer des effets secondaires aux sulfonamides ?\nLes personnes âgées sont-elles plus à risque avec les sulfonamides ?\nLes femmes enceintes peuvent-elles prendre des sulfonamides ?\nLes patients atteints de maladies hépatiques sont-ils à risque ?\nLes antécédents d'infections récurrentes augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D013449?mesh_terms=Blood+Component+Transfusion#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection nécessitant des sulfonamides ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur des symptômes cliniques et des cultures bactériennes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité des sulfonamides ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de sensibilité aux antibiotiques sont réalisés sur des échantillons microbiologiques." } }, { "@type": "Question", "name": "Les sulfonamides sont-ils efficaces contre toutes les bactéries ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur efficacité varie selon le type de bactérie et leur résistance." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une infection bactérienne ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, douleur, rougeur et gonflement peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment confirmer une infection urinaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un examen d'urine et une culture permettent de confirmer une infection urinaire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection traitée par sulfonamides ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, douleur, fatigue et symptômes locaux selon l'infection." } }, { "@type": "Question", "name": "Les sulfonamides provoquent-ils des effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets comme éruptions cutanées, nausées ou réactions allergiques peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique aux sulfonamides ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Éruptions cutanées, démangeaisons, ou gonflement peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surinfection ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Augmentation de la douleur, fièvre persistante et écoulement purulent peuvent indiquer une surinfection." } }, { "@type": "Question", "name": "Les sulfonamides peuvent-ils causer des troubles gastro-intestinaux ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir avec leur utilisation." } }, { "@type": "Question", "name": "Comment prévenir les infections nécessitant des sulfonamides ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une bonne hygiène, se faire vacciner et éviter les contacts avec des malades." } }, { "@type": "Question", "name": "Les sulfonamides peuvent-ils être utilisés en prophylaxie ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être prescrits en prophylaxie pour prévenir certaines infections." } }, { "@type": "Question", "name": "Quelles mesures d'hygiène sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Se laver les mains régulièrement et éviter le partage d'objets personnels." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir les infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations peuvent réduire le risque d'infections bactériennes." } }, { "@type": "Question", "name": "Comment éviter la résistance aux antibiotiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser les antibiotiques uniquement lorsque prescrit et suivre les recommandations médicales." } }, { "@type": "Question", "name": "Comment les sulfonamides sont-ils administrés ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement administrés par voie orale ou intraveineuse selon l'infection." } }, { "@type": "Question", "name": "Quelle est la posologie habituelle des sulfonamides ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie selon l'infection, mais doit être prescrite par un médecin." } }, { "@type": "Question", "name": "Les sulfonamides peuvent-ils être combinés avec d'autres antibiotiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être utilisés en association pour élargir le spectre d'action." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors d'un traitement par sulfonamides ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier pour surveiller les effets secondaires et l'efficacité est recommandé." } }, { "@type": "Question", "name": "Les sulfonamides sont-ils efficaces contre les infections virales ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, les sulfonamides ne sont pas efficaces contre les infections virales." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les sulfonamides ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions allergiques graves, des troubles sanguins ou des lésions hépatiques peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer une réaction allergique sévère aux sulfonamides ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Cesser immédiatement le traitement et consulter un médecin pour un traitement approprié." } }, { "@type": "Question", "name": "Les sulfonamides peuvent-ils causer des troubles rénaux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles rénaux peuvent survenir, nécessitant une surveillance de la fonction rénale." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre élevée, éruption cutanée étendue ou difficulté respiratoire peuvent indiquer une complication." } }, { "@type": "Question", "name": "Les sulfonamides peuvent-ils interagir avec d'autres médicaments ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent interagir avec d'autres médicaments, augmentant le risque d'effets secondaires." } }, { "@type": "Question", "name": "Qui est à risque de développer des effets secondaires aux sulfonamides ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents d'allergies médicamenteuses sont à risque accru." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les sulfonamides ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles prendre des sulfonamides ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation doit être évitée, car elle peut affecter le fœtus. Consultez un médecin." } }, { "@type": "Question", "name": "Les patients atteints de maladies hépatiques sont-ils à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent avoir un risque accru d'effets indésirables et nécessitent une surveillance." } }, { "@type": "Question", "name": "Les antécédents d'infections récurrentes augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents d'infections récurrentes peuvent nécessiter un traitement plus agressif." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 19/04/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

31 au total
└─

Bumétanide

Bumetanide D002034 - D02.886.590.700.150
└─

Diclofénamide

Dichlorphenamide D004005 - D02.886.590.700.410
└─

Mafénide

Mafenide D008272 - D02.886.590.700.570
└─

Méfruside

Mefruside D008529 - D02.886.590.700.575
└─

Probénécide

Probenecid D011339 - D02.886.590.700.625
└─

Sulfamides

Sulfanilamides D013424 - D02.886.590.700.725
└─

Sulfasalazine

Sulfasalazine D012460 - D02.886.590.700.730
└─

Tamsulosine

Tamsulosin D000077409 - D02.886.590.700.863
└─

Xipamide

Xipamide D014988 - D02.886.590.700.975
└─└─

Furosémide

Furosemide D005665 - D02.886.590.700.725.300
└─└─

Sulfacétamide

Sulfacetamide D013409 - D02.886.590.700.725.650
└─└─

Sulfachlorpyridazine

Sulfachlorpyridazine D013410 - D02.886.590.700.725.700
└─└─

Sulfadiazine

Sulfadiazine D013411 - D02.886.590.700.725.755
└─└─

Sulfadiméthoxine

Sulfadimethoxine D013412 - D02.886.590.700.725.760
└─└─

Sulfadoxine

Sulfadoxine D013413 - D02.886.590.700.725.765
└─└─

Sulfaguanidine

Sulfaguanidine D013414 - D02.886.590.700.725.810
└─└─

Sulfalène

Sulfalene D013415 - D02.886.590.700.725.850
└─└─

Sulfamérazine

Sulfamerazine D013416 - D02.886.590.700.725.853
└─└─

Sulfamétoxydiazine

Sulfameter D013417 - D02.886.590.700.725.857
└─└─

Sulfadimidine

Sulfamethazine D013418 - D02.886.590.700.725.862
└─└─

Sulfaméthoxazole

Sulfamethoxazole D013420 - D02.886.590.700.725.867
└─└─

Sulfaméthoxypyridazine

Sulfamethoxypyridazine D013421 - D02.886.590.700.725.872
└─└─

Sulfamonométhoxine

Sulfamonomethoxine D013422 - D02.886.590.700.725.877
└─└─

Sulfamoxole

Sulfamoxole D013423 - D02.886.590.700.725.882
└─└─

Sulfanilamide

Sulfanilamide D000077145 - D02.886.590.700.725.885
└─└─

Sulfapyridine

Sulfapyridine D013427 - D02.886.590.700.725.900
└─└─

Sulfaquinoxaline

Sulfaquinoxaline D013428 - D02.886.590.700.725.925
└─└─

Sulfisomidine

Sulfisomidine D013443 - D02.886.590.700.725.940
└─└─

Sulfafurazol

Sulfisoxazole D013444 - D02.886.590.700.725.945
└─└─└─

Sulfadiazine d'argent

Silver Sulfadiazine D012837 - D02.886.590.700.725.755.800
└─└─└─

Sulfaméthizol

Sulfamethizole D013419 - D02.886.590.700.725.935.813

Auteurs principaux

Reihane Ghomashi

3 publications dans cette catégorie

Affiliations :
  • Department of Medicinal Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran.

Shakila Ghomashi

3 publications dans cette catégorie

Affiliations :
  • Department of Medicinal Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran.

Hamidreza Aghaei

3 publications dans cette catégorie

Affiliations :
  • Department of Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran.

Ahmad Reza Massah

3 publications dans cette catégorie

Affiliations :
  • Department of Chemistry, Shahreza Branch, Islamic Azad University, P.O. Box 311-86145, Shahreza, Isfahan, Iran.
  • Razi Chemistry Research Center (RCRC), Shahreza Branch, Islamic Azad University, Isfahan, Iran.

Satoru Suzuki

3 publications dans cette catégorie

Affiliations :
  • Leading Academia in Marine and Environment Pollution Research (LaMer), Center for Marine Environmental Studies (CMES), Ehime University, Japan.
Publications dans "Sulfonamides" :

David A Khan

2 publications dans cette catégorie

Affiliations :
  • Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Publications dans "Sulfonamides" :

Ligui Wu

2 publications dans cette catégorie

Affiliations :
  • College of Environmental Science and Engineering, Tongji University, Shanghai 200092, China; School of Life Science, Jinggangshan University, Ji'an 343009, China.

Lingling Rong

2 publications dans cette catégorie

Affiliations :
  • School of Life Science, Jinggangshan University, Ji'an 343009, China.

Xiaoming Zou

2 publications dans cette catégorie

Affiliations :
  • School of Life Science, Jinggangshan University, Ji'an 343009, China. Electronic address: zouxming_80@hotmail.com.

Jun Chen

2 publications dans cette catégorie

Affiliations :
  • Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Publications dans "Sulfonamides" :

Andrea Angeli

2 publications dans cette catégorie

Affiliations :
  • Section of Pharmaceutical and Nutraceutical Sciences, Department of Neurofarba, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino (Florence), Italy.
Publications dans "Sulfonamides" :

Fabrizio Carta

2 publications dans cette catégorie

Affiliations :
  • Section of Pharmaceutical and Nutraceutical Sciences, Department of Neurofarba, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino (Florence), Italy.
Publications dans "Sulfonamides" :

Claudiu T Supuran

2 publications dans cette catégorie

Affiliations :
  • Section of Pharmaceutical and Nutraceutical Sciences, Department of Neurofarba, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino (Florence), Italy.
Publications dans "Sulfonamides" :

Clemente Capasso

2 publications dans cette catégorie

Affiliations :
  • Institute of Biosciences and Bioresources, CNR, Via Pietro Castellino 111, 80131 Napoli, Italy.
Publications dans "Sulfonamides" :

Weijuan Yang

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, College of Plant Protection, Fujian Agriculture and Forestry University, Fuzhou 350002, China.

FengFu Fu

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory for Analytical Science of Food Safety and Biology of MOE, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China.

Takayoshi Awakawa

2 publications dans cette catégorie

Affiliations :
  • Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-8657, Japan.
Publications dans "Sulfonamides" :

Ikuro Abe

2 publications dans cette catégorie

Affiliations :
  • Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-8657, Japan.
Publications dans "Sulfonamides" :

Aya Kadoya

2 publications dans cette catégorie

Affiliations :
  • Center for Marine Environmental Studies, Ehime University, Matsuyama, Ehime, 790-8577, Japan.
Publications dans "Sulfonamides" :

Patrick L Purder

1 publication dans cette catégorie

Affiliations :
  • Department of Organic Chemistry and Biochemistry, Clemens-Schöpf-Institute, Technical University Darmstadt, Alarich-Weiss-Straße 4, 64287 Darmstadt, Germany.
Publications dans "Sulfonamides" :

Sources (10000 au total)

Balanced blood component resuscitation in trauma: Does it matter equally at different transfusion volumes?

It remains unclear whether the association between balanced blood component transfusion and lower mortality is generalizable to trauma patients receiving varying transfusion volumes. We sought to stud... Adult patients in the 2013 to 2018 American College of Surgeons Trauma Quality Improvement Program database receiving ≥6 red blood cell, ≥1 platelet, and ≥1 fresh frozen plasma within 4 hours were inc... A total of 14,549 patients were included. In patients receiving 6 to 10 units of red blood cells, red blood cell:platelet ratios were not associated with 4-hour mortality, and only red blood cell:fres... The association between balanced blood component transfusion and 4-hour mortality is not homogenous in trauma patients requiring different transfusion volumes and is specifically less evident in patie...

Influence of the leukoreduction moment of blood components on the clinical outcomes of transfused patients in the emergency department.

to investigate the influence of the leukoreduction moment (preor post-storage) of blood components on the clinical outcomes of patients transfused in the emergency department.... retrospective cohort study of patients aged 18 years or older who received preor post-storage leukoreduced red blood cell or platelet concentrate in the emergency department and remained in the instit... in a sample of 373 patients (63.27% male, mean age 54.83) and 643 transfusions (69.98% red blood cell), it was identified that the leukoreduction moment influenced the length of hospital stay (p<0.009... patients who received pre-storage leukoreduced blood components in the emergency department had a shorter length of hospital stay....

Hypocalcemia in Trauma is Determined by the Number of Units Transfused, Not Whole Blood Versus Component Therapy.

Blood component resuscitation is associated with hypocalcemia (HC) (iCal <0.9 mmol/L) that contributes to coagulopathy and death in trauma patients. It is unknown whether or not whole blood (WB) resus... This is a retrospective review of all adult trauma patients who received WB from July 2018 to December 2020. Variables included transfusions, ionized calcium levels, and calcium replacement. Patients ... Two hundred twenty-three patients received WB and met the inclusion criteria. 107 (48%) received WB only. HC occurred in 13% of patients who received more than one WB unit compared to 29% of WB and ot... HC and failure to correct HC are significant risk factors for mortality in trauma. Resuscitations with WB only and WB in combination with other blood components are associated with HC especially when ...

Parents' understanding and experiences of blood component transfusion in the neonatal intensive care unit: A qualitative study.

Blood component transfusion is a common intervention in the neonatal intensive care unit (NICU). Parents consent on their babies' behalf. This study aimed to explore parents' understandings and experi... A "low inference" qualitative descriptive semi-structured interview approach was utilised. Grounded theory was employed. Parents described their memories of babies' transfusions, their responses to th... A purposive sample of 17 parents whose babies required blood transfusion in the NICU participated. Parents talked about their initial fears of transfusion, later replaced by confidence in the process ... Parents in our study trust information from the healthcare professionals caring for their baby and would like more specific information about how blood transfusion will impact their baby, in a variety...

Blood component-associated acute transfusion reactions in pediatric patients: experience of a tertiary care hospital.

The transfusion of blood products is a life-saving clinical practice in patients with bleeding, hemoglobinopathy, and cancer. It was aimed herein to analyze the frequency and types of blood component-... This retrospective study was conducted at a tertiary care academic pediatric hospital.... During the study period, 30,811 transfusions were administered to 25,448 patients. There were 103 ATRs detected in 81 patients (0.33%; 3.34 reactions per 1000 transfusions, mean age 8.3 ± 5.98 years, ... Within our hospital, pediatric hematology-oncology wards and the stem cell transplantation unit had the most frequent ATR reports; therefore, when transfusions are carried out, increased attention sho...

Transfusion-related cost comparison of trauma patients receiving whole blood versus component therapy.

With the emergence of whole blood (WB) in trauma resuscitation, cost-related comparisons are of significant importance to providers, blood banks, and hospital systems throughout the country. The objec... A retrospective review of adult and pediatric trauma patients who received either LTO+WB or CT from time of injury to within 4 hours of arrival was performed. Annual mean cost per unit of blood produc... Prehospital LTO+WB transfusion began at this institution in January 2018. After the initiation of the WB transfusion, the mean annual cost decreased 17.3% for all blood products, and the average net d... With increased use of LTO+WB for resuscitation, cost comparison is of significant importance to all stakeholders. Low titer O+ WB was associated with reduced cost in severely injured patients. Ongoing... Therapeutic/Care Management; Level IV....

The abrogated role of premedication in the prevention of transfusion-associated adverse reactions in outpatients receiving leukocyte-reduced blood components.

Although it remains controversial, premedication before transfusion is a common clinical practice to prevent transfusion-associated adverse reactions (TAARs) in Taiwan. Thus, we aimed to investigate w... Clinical data from outpatients receiving transfusion therapy, including predisposing diseases, histories of transfusion and TAARs, premedication and the occurrence of TAARs in the period April 2017 to... A total of 5018 blood units were transfused to 803 outpatients, with 2493 transfusion events reported in the study interval. The most frequently transfused component was leukocyte-reduced packed red c... Decreased premedication was not associated with increased incidence of TAARs in outpatients; these findings provide important evidence to support the need to revise clinical practices in the era of le...

How to improve issuing, transfusion and follow-up of blood components in Southern and Eastern Mediterranean countries? A benchmark assessment.

To determine the existence of guidelines regarding the appropriate clinical use of blood and blood components, transfusion requests, and blood issuing/reception documents and procedures. The different...

Outcomes of Transfusion With Whole Blood, Component Therapy, or Both in Adult Civilian Trauma Patients: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis was conducted to compare outcomes, including transfusion volume, complications, intensive care unit length of stay, and mortality for adult civilian trauma pat... A systematic review and meta-analysis were conducted using studies that evaluated outcomes of transfusion of WB, COMP, or WB + COMP for adult civilian trauma patients. A search of PubMed, Embase, and ... This study identified an increased risk of 24-h mortality with COMP versus WB + COMP (relative risk: 1.40 [1.10, 1.78]) and increased transfusion volumes of red blood cells with COMP versus WB at 6 an... Transfusion with WB + COMP is associated with lower 24-h mortality versus COMP and transfusion with WB is associated with a lower volume of red blood cells transfused at both 6 and 24 h. Based on thes...